Status:
WITHDRAWN
Effects of DPP4 Inhibition on COVID-19
Lead Sponsor:
University of Miami
Conditions:
Coronavirus Infection
Type 2 Diabetes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-...
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus (T2DM) as per American Diabetes Association (ADA) guidelines
- Age ≥ 18
- Confirmed COVID-19
- Mild COVID-19 defined as any of the following: fever, malaise, cough, headache, sore throat, myalgia, nasal congestion, diarrhea
- Moderate COVID-19 is defined as \> 2 of the following in non-intubated patients: any symptom of mild disease, radiographic imaging (chest x-ray or lung ultrasound) with bilateral ground glass opacities or bilateral consolidations, SpO2 \<90% up to 5L Nasal Cannula (NC)
- No additional signs or symptoms of severe COVID-19.
Exclusion
- Type 1 Diabetes Mellitus (T1DM) diabetes, as per ADA guidelines
- History of Diabetic Ketoacidosis (DKA)
- History of acute pancreatitis
- Chronic or Acute Renal Failure with Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 m2
Key Trial Info
Start Date :
June 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2021
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04341935
Start Date
June 30 2021
End Date
December 30 2021
Last Update
June 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Miami
Miami, Florida, United States, 33136